NS-003
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 12/19/2023
Pipeline Type
New Drugs in Development
Phase Of Development
Preclinical
Sponsors and Collaborators
NanoScrips
Mechanism of Action
GABA
Mechanism Description
NS-003 is a prodrug-nanoparticle of valproic acid which significantly improved the half-life of valproic acid and increased the safety and efficacy in PTZ induced epilepsy mouse model. Hence, NS-003 is a candidate for 505(b)2 regulatory approval path.
Populations Tested In
N/A
Other Resources
Special FDA Designation
Rare Pediatric Disease
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
A publication in peer-review research journal. Global patent pending publication.
Location of Clinical Trials
N/A. In Pre-IND stage
Clinical Trial link